Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback